↓ Skip to main content

Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa

Overview of attention for article published in BMC Infectious Diseases, June 2017
Altmetric Badge

About this Attention Score

  • Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter
3 tweeters

Citations

dimensions_citation
16 Dimensions

Readers on

mendeley
102 Mendeley
You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output. Click here to find out more.
Title
Early experiences from one of the first treatment programs for chronic hepatitis B in sub-Saharan Africa
Published in
BMC Infectious Diseases, June 2017
DOI 10.1186/s12879-017-2549-8
Pubmed ID
Authors

Hanna Aberra, Hailemichael Desalegn, Nega Berhe, Girmay Medhin, Kathrine Stene-Johansen, Svein Gunnar Gundersen, Asgeir Johannessen

Abstract

Treatment for chronic hepatitis B (CHB) is virtually absent in sub-Saharan Africa. Here we present early experiences from a pilot program for treatment of CHB in Ethiopia. Adults (≥18 years) with CHB were included in a cohort study at St. Paul's Hospital Millennium Medical College, Addis Ababa, from February 2015. The baseline assessment included liver function tests, viral markers and transient elastography (Fibroscan 402, Echosense, France). Logistic regression models were used to identify predictors of fibrosis. Tenofovir disoproxil fumarate (TDF) was initiated based on the European Association for the Study of the Liver (EASL) criteria, with some modifications. The initial 300 patients underwent a more comprehensive evaluation and are presented here. One-hundred-and-thirty-eight patients (46.0%) were women and median age was 30 years (interquartile range 26-40). Co-infections were rare: four patients (1.3%) were anti-HCV positive, 11 (3.7%) were anti-HDV positive, whereas 5 (1.7%) had HIV-infection. The majority were hepatitis B e-antigen (HBeAg) negative (n = 262; 90.7%) and had a normal (≤40 U/L) alanine aminotransferase (ALT) (n = 245; 83.1%). Of 268 patients with a valid Fibroscan result, 79 (29.5%) had significant fibrosis (>7.9 kPa). Independent predictors of fibrosis were male sex, age > 35 years and viral load >20,000 IU/ml. In total, 74 patients (24.7%) started TDF therapy, of whom 46 (62.2%) had cirrhosis. The majority were HBeAg negative and had normal ALT. However, one quarter of the patients were in need of antiviral treatment, underscoring the need to scale up CHB treatment on the African continent. NCT02344498 ( ClinicalTrials.gov identifier). Registered 16 January 2015.

Twitter Demographics

The data shown below were collected from the profiles of 3 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 102 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Unknown 102 100%

Demographic breakdown

Readers by professional status Count As %
Student > Master 23 23%
Student > Postgraduate 12 12%
Student > Ph. D. Student 11 11%
Researcher 10 10%
Student > Bachelor 7 7%
Other 15 15%
Unknown 24 24%
Readers by discipline Count As %
Medicine and Dentistry 32 31%
Nursing and Health Professions 17 17%
Immunology and Microbiology 6 6%
Pharmacology, Toxicology and Pharmaceutical Science 5 5%
Agricultural and Biological Sciences 4 4%
Other 14 14%
Unknown 24 24%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 28 July 2017.
All research outputs
#8,868,879
of 11,530,102 outputs
Outputs from BMC Infectious Diseases
#2,750
of 4,281 outputs
Outputs of similar age
#157,930
of 233,690 outputs
Outputs of similar age from BMC Infectious Diseases
#59
of 101 outputs
Altmetric has tracked 11,530,102 research outputs across all sources so far. This one is in the 19th percentile – i.e., 19% of other outputs scored the same or lower than it.
So far Altmetric has tracked 4,281 research outputs from this source. They receive a mean Attention Score of 4.2. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 233,690 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 26th percentile – i.e., 26% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 101 others from the same source and published within six weeks on either side of this one. This one is in the 37th percentile – i.e., 37% of its contemporaries scored the same or lower than it.